Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib

Bleeding events have been observed among a subgroup of chronic lymphocytic leukaemia (CLL) patients treated with ibrutinib. We analysed data from two studies of single‐agent ibrutinib to better characterize bleeding events and pattern of anticoagulation and antiplatelet use. Among 327 ibrutinib‐trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Jeffrey A., Hillmen, Peter, Coutre, Steven, Tam, Constantine, Furman, Richard R., Barr, Paul M., Schuster, Stephen J., Kipps, Thomas J., Flinn, Ian W., Jaeger, Ulrich, Burger, Jan A., Cheng, Mei, Ninomoto, Joi, James, Danelle F., Byrd, John C., O'Brien, Susan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Platelets, Haemostasis and Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084297/
https://www.ncbi.nlm.nih.gov/pubmed/28397242
http://dx.doi.org/10.1111/bjh.14660

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084297/
https://www.ncbi.nlm.nih.gov/pubmed/28397242
http://dx.doi.org/10.1111/bjh.14660

Ejemplares similares